In Asia-Pacific Biotech News, Life Sciences Partner Addresses Proposed China Pharmaceutical Regulatory Changes
The Chinese government recently submitted a second draft of the Drug Administration Law of the People’s Republic of China to the Standing Committee of the National People’s Congress of China for deliberation. Life sciences partner Katherine Wang (Shanghai) authored an article published by Asia-Pacific Biotech News on June 12 that discusses the major changes.
Ms. Wang notes that while the proposed draft codifies many reform initiatives that accelerate market access of innovative drugs, it also signals aggressive post-approval enforcement and severe sanctions.